BioLife Solutions Inc
BLFS22.430USD
+0.410+1.86%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.08BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über BioLife Solutions Inc Unternehmen
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions Inc Informationen
BörsenkürzelBLFS
Name des UnternehmensBioLife Solutions Inc
IPO-datumNov 22, 1989
CEODe Greef (Roderick)
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeNov 22
AddresseSuite 310
StadtBOTHELL
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl98021
Telefon14254011400
Websitehttps://www.biolifesolutions.com/
BörsenkürzelBLFS
IPO-datumNov 22, 1989
CEODe Greef (Roderick)
Führungskräfte von BioLife Solutions Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
251.85K
-405.00%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
149.25K
-335.00%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
66.72K
-990.00%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
48.80K
-241.00%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
38.11K
-3000.00%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
25.93K
-110.00%
Ms. Catherine (Cathy) Coste, CPA
Ms. Catherine (Cathy) Coste, CPA
Independent Director
Independent Director
5.70K
--
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Amy Duross
Ms. Amy Duross
Lead Independent Director
Lead Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
251.85K
-405.00%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
149.25K
-335.00%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
66.72K
-990.00%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
48.80K
-241.00%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
38.11K
-3000.00%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
25.93K
-110.00%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Revenue-Cell processing
25.28M
90.08%
Rental Revenue- Evo and thaw
1.79M
6.38%
Product Revenue- Evo and thaw
968.00K
3.45%
Service Revenue-Evo and thaw
26.00K
0.09%
Nach RegionUSD
Name
Umsatz
Anteil
United States
21.33M
76.00%
Europe & Middle East & Africa (EMEA) (Region)
5.33M
19.00%
Other Countries
1.40M
5.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Revenue-Cell processing
25.28M
90.08%
Rental Revenue- Evo and thaw
1.79M
6.38%
Product Revenue- Evo and thaw
968.00K
3.45%
Service Revenue-Evo and thaw
26.00K
0.09%
Aktionärsstatistik
Aktualisiert: Sat, Nov 15
Aktualisiert: Sat, Nov 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Casdin Capital, LLC
12.37%
T. Rowe Price Investment Management, Inc.
10.76%
BlackRock Institutional Trust Company, N.A.
10.60%
Invesco Advisers, Inc.
7.22%
The Vanguard Group, Inc.
6.40%
Andere
52.65%
Aktionäre
Aktionäre
Anteil
Casdin Capital, LLC
12.37%
T. Rowe Price Investment Management, Inc.
10.76%
BlackRock Institutional Trust Company, N.A.
10.60%
Invesco Advisers, Inc.
7.22%
The Vanguard Group, Inc.
6.40%
Andere
52.65%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
52.44%
Investment Advisor/Hedge Fund
34.07%
Hedge Fund
15.54%
Research Firm
2.31%
Individual Investor
1.99%
Pension Fund
1.60%
Bank and Trust
0.48%
Sovereign Wealth Fund
0.08%
Insurance Company
0.03%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
402
49.86M
109.33%
-743.44K
2025Q3
418
50.60M
112.73%
+431.43K
2025Q2
417
51.14M
109.98%
+2.32M
2025Q1
412
48.78M
108.79%
-2.89M
2024Q4
397
47.68M
109.40%
+879.99K
2024Q3
391
46.15M
113.67%
-1.38M
2024Q2
371
47.55M
108.21%
+1.88M
2024Q1
363
45.48M
113.98%
-6.15M
2023Q4
383
46.46M
115.88%
+36.24K
2023Q3
386
44.68M
106.82%
+2.82M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Casdin Capital, LLC
5.96M
12.37%
-750.00K
-11.18%
Oct 15, 2025
T. Rowe Price Investment Management, Inc.
4.07M
8.45%
-179.85K
-4.24%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.10M
10.6%
+21.37K
+0.42%
Sep 30, 2025
Invesco Advisers, Inc.
3.48M
7.22%
+21.52K
+0.62%
Sep 30, 2025
The Vanguard Group, Inc.
2.96M
6.15%
+70.25K
+2.43%
Sep 30, 2025
State Street Investment Management (US)
1.46M
3.03%
+47.61K
+3.38%
Sep 30, 2025
Fred Alger Management, LLC
1.11M
2.3%
-139.11K
-11.15%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.02M
2.11%
+1.01M
+35792.97%
Sep 30, 2025
Rockefeller Capital Management
1.01M
2.1%
-16.29K
-1.59%
Sep 30, 2025
MFS Investment Management
1.10M
2.28%
-4.74K
-0.43%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco S&P SmallCap Health Care ETF
0.66%
Invesco S&P SmallCap 600 Pure Growth ETF
0.62%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Zacks Small/Mid Cap ETF
0.41%
iShares Micro-Cap ETF
0.2%
State Street SPDR S&P 600 Small Cap Growth ETF
0.15%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.14%
iShares S&P Small-Cap 600 Growth ETF
0.14%
iShares ESG Select Screened S&P Small-Cap ETF
0.09%
Mehr Anzeigen
Invesco S&P SmallCap Health Care ETF
Anteil0.66%
Invesco S&P SmallCap 600 Pure Growth ETF
Anteil0.62%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.52%
Zacks Small/Mid Cap ETF
Anteil0.41%
iShares Micro-Cap ETF
Anteil0.2%
State Street SPDR S&P 600 Small Cap Growth ETF
Anteil0.15%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.15%
Vanguard S&P Small-Cap 600 Growth Index Fund
Anteil0.14%
iShares S&P Small-Cap 600 Growth ETF
Anteil0.14%
iShares ESG Select Screened S&P Small-Cap ETF
Anteil0.09%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
